{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:21:43Z","timestamp":1790911303867,"version":"4.1.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.medmal.2009.10.009","type":"journal-article","created":{"date-parts":[[2009,12,3]],"date-time":"2009-12-03T05:18:18Z","timestamp":1259817498000},"page":"135-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Quelles nouveaut\u00e9s en antibioth\u00e9rapie\u00a0?"],"prefix":"10.1016","volume":"40","author":[{"given":"V.","family":"Cattoir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Daurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2009.10.009_bib1","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.cell.2007.03.004","article-title":"Molecular mechanisms of antibacterial multidrug resistance","volume":"128","author":"Alekshun","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.medmal.2009.10.009_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMp048093","article-title":"The antibiotic pipeline \u2013 challenges, costs, and values","volume":"351","author":"Wenzel","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl. 4","key":"10.1016\/j.medmal.2009.10.009_bib3","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/S0924-8579(09)70004-4","article-title":"What's new on the antimicrobial horizon?","volume":"32","author":"Song","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2009.10.009_bib4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.mib.2005.07.001","article-title":"Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria","volume":"8","author":"Appelbaum","year":"2005","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.medmal.2009.10.009_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1469-0691.2007.01933.x","article-title":"New antimicrobial agents for the treatment of Gram-positive bacterial infections","volume":"14","author":"Aksoy","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medmal.2009.10.009_bib6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.coph.2008.08.001","article-title":"New agents in development for the treatment of bacterial infections","volume":"8","author":"Abbanat","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.medmal.2009.10.009_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(05)70051-7","article-title":"Mechanisms of action of newer antibiotics for Gram-positive pathogens","volume":"5","author":"Hancock","year":"2005","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.medmal.2009.10.009_bib8","first-page":"ii9","article-title":"Linezolid in vitro: mechanism and antibacterial spectrum","volume":"51","author":"Livermore","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2165\/00003495-200161040-00008","article-title":"Linezolid: a review of its use in the management of serious Gram-positive infections","volume":"61","author":"Perry","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2009.10.009_bib10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1128\/AAC.40.3.720","article-title":"In vitro antimicrobial activities and spectra of U-100592\u00a0and U-100766, two novel fluorinated oxazolidinones","volume":"40","author":"Jones","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/AAC.40.4.839","article-title":"In vitro activities of U-100592\u00a0and U-100766, novel oxazolidinone antibacterial agents","volume":"40","author":"Zurenko","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib12","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1128\/AAC.43.6.1469","article-title":"Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans","volume":"43","author":"Goldstein","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003495-199958060-00008","article-title":"Quinupristin\/dalfopristin: a review of its use in the management of serious Gram-positive infections","volume":"58","author":"Lamb","year":"1999","journal-title":"Drugs"},{"issue":"Suppl. A","key":"10.1016\/j.medmal.2009.10.009_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jac\/39.suppl_1.15","article-title":"In-vitro and in-vivo antibacterial activity of quinupristin\/dalfopristin","volume":"39","author":"Bouanchaud","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib15","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2165\/00003495-200767100-00008","article-title":"Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia","volume":"67","author":"Hair","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2009.10.009_bib16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijantimicag.2006.07.017","article-title":"In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin\/dalfopristin","volume":"28","author":"Anastasiou","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2009.10.009_bib17","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/dkh143","article-title":"Daptomycin activity and spectrum: a worldwide sample of 6737\u00a0clinical Gram-positive organisms","volume":"53","author":"Streit","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.diagmicrobio.2008.01.016","article-title":"Update of the in vitro activity of daptomycin tested against 6710\u00a0Gram-positive cocci isolated in North America (2006)","volume":"61","author":"Castanheira","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2009.10.009_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/jac\/48.2.219","article-title":"The in vitro activity of daptomycin against 514\u00a0Gram-positive aerobic clinical isolates","volume":"48","author":"King","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib20","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1128\/AAC.45.6.1919-1922.2001","article-title":"In vitro activities of daptomycin against 2,789\u00a0clinical isolates from 11\u00a0North American medical centers","volume":"45","author":"Barry","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/AAC.47.1.337-341.2003","article-title":"In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307\u00a0Gram-positive anaerobic and 31\u00a0Corynebacterium clinical isolates","volume":"47","author":"Goldstein","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib22","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1128\/AAC.49.1.408-413.2005","article-title":"Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic Gram-positive species, actinomycetes, and lactobacilli","volume":"49","author":"Goldstein","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1586\/14787210.5.4.557","article-title":"Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria","volume":"5","author":"Decousser","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.medmal.2009.10.009_bib24","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1128\/AAC.47.6.1968-1971.2003","article-title":"In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and corynebacteria","volume":"47","author":"Goldstein","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib25","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1128\/AAC.00286-06","article-title":"In vitro activities of dalbavancin and 12\u00a0other agents against 329\u00a0aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections","volume":"50","author":"Goldstein","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1586\/14787210.6.1.67","article-title":"Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections","volume":"6","author":"Zhanel","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.medmal.2009.10.009_bib27","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1128\/AAC.01398-07","article-title":"In vitro activity of telavancin against resistant Gram-positive bacteria","volume":"52","author":"Krause","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib28","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/dkh156","article-title":"Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria","volume":"53","author":"King","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib29","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1128\/AAC.48.6.2149-2152.2004","article-title":"In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic Gram-positive species and Corynebacterium spp","volume":"48","author":"Goldstein","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2217\/17460913.3.3.251","article-title":"Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens","volume":"3","author":"Crandon","year":"2008","journal-title":"Future Microbiol"},{"key":"10.1016\/j.medmal.2009.10.009_bib31","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1128\/AAC.41.10.2165","article-title":"In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide","volume":"41","author":"Biavasco","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/48.2.283","article-title":"In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci","volume":"48","author":"Noviello","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.anaerobe.2004.10.005","article-title":"In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic Gram-positive cocci","volume":"11","author":"Citron","year":"2005","journal-title":"Anaerobe"},{"key":"10.1016\/j.medmal.2009.10.009_bib34","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1128\/AAC.00131-06","article-title":"The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics","volume":"50","author":"Long","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib35","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1517\/14656566.8.14.2279","article-title":"Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era","volume":"8","author":"Ziglam","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.medmal.2009.10.009_bib36","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2165\/00003495-200565100-00002","article-title":"Tigecycline: a novel glycylcycline","volume":"65","author":"Rubinstein","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2009.10.009_bib37","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2165\/00003495-200565150-00013","article-title":"Ertapenem: a review of its use in the treatment of bacterial infections","volume":"65","author":"Keating","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2009.10.009_bib38","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/14787210.5.5.793","article-title":"Carbapenems in the USA: focus on doripenem","volume":"5","author":"Lister","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.medmal.2009.10.009_bib39","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2165\/00003495-200868140-00007","article-title":"Doripenem: a review of its use in the treatment of bacterial infections","volume":"68","author":"Keam","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2009.10.009_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/dkl219","article-title":"Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence","volume":"58","author":"Falagas","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijantimicag.2006.08.030","article-title":"Linezolid for the treatment of adults with bone and joint infections","volume":"29","author":"Falagas","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2009.10.009_bib42","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/jac\/dkh409","article-title":"Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study","volume":"54","author":"Senneville","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib43","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.clinthera.2006.08.001","article-title":"Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study","volume":"28","author":"Senneville","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.medmal.2009.10.009_bib44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14787210.5.2.177","article-title":"Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections","volume":"5","author":"Kanafani","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.medmal.2009.10.009_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000109868","article-title":"Daptomycin: a review 4\u00a0years after first approval","volume":"81","author":"Sauermann","year":"2008","journal-title":"Pharmacology"},{"key":"10.1016\/j.medmal.2009.10.009_bib46","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1086\/520655","article-title":"Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus","volume":"45","author":"Boucher","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.10.009_bib47","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2007.02.012","article-title":"Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence","volume":"30","author":"Falagas","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2009.10.009_bib48","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijantimicag.2008.12.007","article-title":"Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE)","volume":"33","author":"Mohr","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 4","key":"10.1016\/j.medmal.2009.10.009_bib49","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/S0924-8579(09)70005-6","article-title":"A review of tigecycline \u2013 the first glycylcycline","volume":"32","author":"Peterson","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2009.10.009_bib50","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jac\/dki248","article-title":"Tigecycline","volume":"56","author":"Pankey","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/AAC.47.1.400-404.2003","article-title":"Activities of the glycylcycline tigecycline (GAR-936) against 1,924\u00a0recent European clinical bacterial isolates","volume":"47","author":"Milatovic","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.diagmicrobio.2005.06.004","article-title":"In vitro activity of tigecycline against 3989\u00a0Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)","volume":"52","author":"Bouchillon","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2009.10.009_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diagmicrobio.2005.06.001","article-title":"In vitro activity of tigecycline against 6792\u00a0Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)","volume":"52","author":"Hoban","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2009.10.009_bib54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijantimicag.2008.07.031","article-title":"Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)","volume":"33","author":"Bouchillon","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2009.10.009_bib55","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1128\/AAC.00625-07","article-title":"Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase\u00a03\u00a0clinical trials for tigecycline","volume":"51","author":"Tuckman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jac\/dkm397","article-title":"MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli","volume":"61","author":"Keeney","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.medmal.2009.10.009_bib57","first-page":"e1","article-title":"Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies","volume":"34","author":"Entenza","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2009.10.009_bib58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1586\/14787210.6.5.557","article-title":"Establishing the role of tigecycline in an era of antimicrobial resistance","volume":"6","author":"Schafer","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.medmal.2009.10.009_bib59","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.2165\/0003495-200868180-00008","article-title":"Tigecycline: in community-acquired pneumonia","volume":"68","author":"McKeage","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2009.10.009_bib60","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2009.10.009_bib61","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jac\/dkg404","article-title":"Ertapenem, the first of a new group of carbapenems","volume":"52","author":"Shah","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib62","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/14787210.3.1.23","article-title":"Ertapenem: review of a new carbapenem","volume":"3","author":"Zhanel","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.medmal.2009.10.009_bib63","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14656566.8.2.237","article-title":"Ertapenem: the new carbapenem 5\u00a0years after first FDA licensing for clinical practice","volume":"8","author":"Burkhardt","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl. 2","key":"10.1016\/j.medmal.2009.10.009_bib64","first-page":"ii11","article-title":"In vitro activity of ertapenem: review of recent studies","volume":"53","author":"Wexler","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 2","key":"10.1016\/j.medmal.2009.10.009_bib65","first-page":"ii23","article-title":"Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians","volume":"53","author":"Nix","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib66","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1517\/13543784.17.5.749","article-title":"Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens","volume":"17","author":"Poulakou","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.medmal.2009.10.009_bib67","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clinthera.2009.01.013","article-title":"Doripenem monohydrate, a broad-spectrum carbapenem antibiotic","volume":"31","author":"Matthews","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.medmal.2009.10.009_bib68","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00128071-200809040-00004","article-title":"Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin","volume":"9","author":"Zhanel","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.medmal.2009.10.009_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2008.12.012","article-title":"Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)","volume":"34","author":"Barbour","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2009.10.009_bib70","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.diagmicrobio.2008.06.003","article-title":"In vitro activity of ceftobiprole, linezolid, tigecycline, and 23\u00a0other antimicrobial agents against Staphylococcus aureus isolates in China","volume":"62","author":"Wang","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2009.10.009_bib71","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1128\/AAC.00336-08","article-title":"In vitro activity of ceftobiprole against pathogens from two phase\u00a03\u00a0clinical trials of complicated skin and skin structure infections","volume":"52","author":"Amsler","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib72","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diagmicrobio.2008.02.008","article-title":"Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005\u20132006)","volume":"61","author":"Fritsche","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2009.10.009_bib73","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.diagmicrobio.2008.02.013","article-title":"Pharmacokinetic and pharmacodynamic profile of ceftobiprole","volume":"61","author":"Lodise","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2009.10.009_bib74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/17460913.4.1.25","article-title":"Ceftaroline: a cephalosporin with expanded Gram-positive activity","volume":"4","author":"Kanafani","year":"2009","journal-title":"Future Microbiol"},{"key":"10.1016\/j.medmal.2009.10.009_bib75","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/AAC.49.8.3501-3512.2005","article-title":"Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains","volume":"49","author":"Sader","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib76","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2165\/00003495-200868050-00006","article-title":"Dalbavancin","volume":"68","author":"Anderson","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2009.10.009_bib77","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1592\/phco.28.4.458","article-title":"Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious Gram-positive infections","volume":"28","author":"Leonard","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.medmal.2009.10.009_bib78","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1517\/13543784.15.4.417","article-title":"Oritavancin \u2013 an investigational glycopeptide antibiotic","volume":"15","author":"Ward","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.medmal.2009.10.009_bib79","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijantimicag.2008.06.032","article-title":"Clinical studies of garenoxacin","volume":"32","author":"Takagi","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2009.10.009_bib80","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1358\/dot.2008.44.7.1219561","article-title":"Sitafloxacin hydrate for bacterial infections","volume":"44","author":"Anderson","year":"2008","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.medmal.2009.10.009_bib81","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2217\/17460913.4.2.131","article-title":"Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections","volume":"4","author":"Morgan","year":"2009","journal-title":"Future Microbiol"},{"key":"10.1016\/j.medmal.2009.10.009_bib82","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dkn511","article-title":"Temocillin revived","volume":"63","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib83","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/526772","article-title":"Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic","volume":"46","author":"Billeter","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.10.009_bib84","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1517\/14656566.9.12.2197","article-title":"A new lipoglycopeptide: telavancin","volume":"9","author":"Nannini","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.medmal.2009.10.009_bib85","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/14787210.3.3.325","article-title":"Oritavancin: a new avenue for resistant Gram-positive bacteria","volume":"3","author":"Mercier","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.medmal.2009.10.009_bib86","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10096-003-0907-5","article-title":"In vitro antibacterial activity and pharmacodynamics of new quinolones","volume":"22","author":"Dalhoff","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2009.10.009_bib87","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jac\/49.1.177","article-title":"The in vitro activity of BMS-284756, a new des-fluorinated quinolone","volume":"49","author":"Weller","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib88","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1128\/AAC.47.3.910-916.2003","article-title":"Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates","volume":"47","author":"Hecht","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib89","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.diagmicrobio.2006.12.006","article-title":"In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004)","volume":"58","author":"Sader","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2009.10.009_bib90","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1128\/AAC.38.10.2504","article-title":"In vitro activity of DU-6859a against anaerobic bacteria","volume":"38","author":"Wexler","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib91","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1128\/AAC.39.12.2822","article-title":"In vitro antibacterial activity of DU-6859a, a new fluoroquinolone","volume":"39","author":"Nakane","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib92","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1128\/AAC.44.4.1102-1107.2000","article-title":"In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796\u00a0clinical bacterial isolates","volume":"44","author":"Milatovic","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib93","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/jac\/46.3.465","article-title":"In vitro activity of an evernimicin derivative, SCH27899, against anaerobic bacteria and Propionibacterium acnes","volume":"46","author":"Tanaka","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib94","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1016\/j.bmcl.2003.07.023","article-title":"Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria","volume":"13","author":"Schneider","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.medmal.2009.10.009_bib95","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1517\/13543784.16.9.1441","article-title":"Iclaprim","volume":"16","author":"Kohlhoff","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.medmal.2009.10.009_bib96","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1128\/AAC.00129-09","article-title":"Potency and bactericidal activity of iclaprim against recent clinical Gram-positive isolates","volume":"53","author":"Sader","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib97","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1128\/AAC.22.4.535","article-title":"In vitro activity of temocillin (BRL 17421), a novel beta-lactam antibiotic","volume":"22","author":"Van Landuyt","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib98","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/dkl043","article-title":"Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England","volume":"57","author":"Livermore","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib99","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1128\/AAC.00290-09","article-title":"Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli","volume":"53","author":"Adams-Haduch","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jcf.2005.12.005","article-title":"Temocillin in the treatment of Burkholderia cepacia infection in cystic fibrosis","volume":"5","author":"Lekkas","year":"2006","journal-title":"J Cyst Fibros"},{"issue":"Suppl. 3","key":"10.1016\/j.medmal.2009.10.009_bib101","first-page":"iii31","article-title":"Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients","volume":"51","author":"Montecalvo","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib102","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1128\/AAC.47.7.2334-2338.2003","article-title":"In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria","volume":"47","author":"Citron","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.10.009_bib103","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1586\/14787210.4.6.939","article-title":"Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent","volume":"4","author":"Fulco","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.medmal.2009.10.009_bib104","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrmicro727","article-title":"Where will new antibiotics come from?","volume":"1","author":"Walsh","year":"2003","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.medmal.2009.10.009_bib105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijantimicag.2009.02.005","article-title":"Future antibiotics scenarios: is the tide starting to turn?","volume":"34","author":"Theuretzbacher","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 1","key":"10.1016\/j.medmal.2009.10.009_bib106","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/521860","article-title":"Treatment of Clostridium difficile infection","volume":"46","author":"Gerding","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X09003242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X09003242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:07:31Z","timestamp":1759972051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X09003242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0399077X09003242"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2009.10.009","relation":{},"ISSN":["0399-077X"],"issn-type":[{"value":"0399-077X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quelles nouveaut\u00e9s en antibioth\u00e9rapie\u00a0?","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2009.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}